VERDE SCIENCE, INC. Inactive Instrument
Verde Science, Inc. Share Price Other OTC
Equities
VRCI
US92337L2034
Biotechnology & Medical Research
| Sales 2013 | - | Sales 2014 | - | Capitalization | 655K 54.59M |
|---|---|---|---|---|---|
| Net income 2013 | - 0 | Net income 2014 | -2M -167M | EV / Sales 2013 | - |
| Net Debt 2013 | 252K 20.98M | Net Debt 2014 | 259K 21.58M | EV / Sales 2014 | - |
| P/E ratio 2013 |
-9.91
x | P/E ratio 2014 |
-0.23
x | Employees | - |
| Yield 2013 * |
-
| Yield 2014 |
-
| Free-Float | 90.01% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/07/31 | |
Craig Alford
BRD | Director/Board Member | 61 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Craig Alford
BRD | Director/Board Member | 61 | - |
| Chief Executive Officer | 58 | 31/07/31 |
Verde Science, Inc. is a pharmaceutical research and development company. The Company is engaged in medical science consulting business. The Company is focused on the discovery of drugs and treatment modalities, as well as diagnostic devices and pharmaceutical delivery systems for the treatment of diseases and medical issues. The Company is focused on developing medicinal formulations from cannabinoids and tetrahydrocannabinol (THC) compounds for the treatment of various issues, such as migraines, glaucoma, loss of appetite from cancer therapies, and other medical issues. The Company is focused on launching its THC Pharmaceutical Development Program by executing a research program, which involves developing formulations preparing protocols for clinical trials.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
